Drugs Targeting RET
- Gavreto (pralsetinib) – approved for stage 4 NSCLC patients with a fusion in RET as detected by a biomarker test.
- Retevmo (selpercatinib) – approved for stage 4 NSCLC patients with a fusion in RET as detected by a biomarker test.